title: Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or α-adrenoceptor antagonist?
authors.affiliation: Plethora Solutions Holdings PLC, London, UK. m.wyllie@globalpharma.co.uk
authors.forename: Michael G
authors.initials: MG
authors.lastname: Wyllie
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D002243:Carbolines / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D000068581:Tadalafil
chemical_list: D000317:Adrenergic alpha-Antagonists; D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil